Breaking Down SG&A Expenses: GSK plc vs Biogen Inc.

A Comparative Analysis of SG&A Expenses: GSK plc vs Biogen Inc.

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of GSK plc and Biogen Inc. from 2014 to 2023. Over this period, GSK consistently outspent Biogen, with SG&A expenses averaging around 9.8 billion annually, nearly four times Biogen's average of 2.3 billion. Notably, GSK's expenses peaked in 2020 at approximately 11.5 billion, reflecting a strategic push during a challenging global health crisis. In contrast, Biogen's highest expenditure was in 2021, reaching 2.7 billion, indicating a more conservative approach. This financial behavior highlights the differing operational strategies of these pharmaceutical giants, with GSK investing heavily in market presence and Biogen focusing on streamlined operations. Such insights are invaluable for investors and industry analysts alike.